Literature DB >> 2777413

Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy.

G Massazza1, A Tomasoni, V Lucchini, P Allavena, E Erba, N Colombo, A Mantovani, M D'Incalci, C Mangioni, R Giavazzi.   

Abstract

Human ovarian carcinomas (HOC) were established s.c. and i.p. in nude mice and the biological characteristics were investigated for 4 xenografts. HOC8 and HOC18, derived respectively from a primary tumor of the ovary and a pleural effusion (from 2 different patients) were established s.c. in nude mice. HOC10 and HOC22, derived from the ascites of 2 patients, were directly established as ascites after i.p. injection in nude mice. The s.c. and i.p. growth behavior of the 4 HOC lines was investigated. HOC18, HOC8 and HOC22 cells produced progressively growing tumor after s.c. injection but HOC10 ascites would not grow s.c. The cell suspension derived from HOC18 only produced carcinomatosis upon i.p. injection, while HOC8 cells produced both ascites and carcinomatosis. The 2 ascites HOC10 and HOC22 produced ascites in nude mice, but only HOC22 formed i.p. carcinomatosis. Histopathological characteristics of the patients' primary tumors persisted in nude mice, regardless of the site of tumor implantation. DNA histograms of the xenografts closely matched the patients' tumors and remained stable at different passages. Cisplatin, adriamycin and cyclophosphamide given i.v. were tested against HOC8 and HOC18 growing s.c. and HOC22 and HOC10 growing i.p. HOC8 showed a significant response to DDP and almost no sensitivity to ADR and CTX. HOC18 showed only moderate growth delay with all 3 drugs. Mice bearing HOC10 and HOC22 ascites had a prolonged survival time after DDP and ADR treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777413     DOI: 10.1002/ijc.2910440320

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Authors:  S John Weroha; Marc A Becker; Sergio Enderica-Gonzalez; Sean C Harrington; Ann L Oberg; Matthew J Maurer; Sarah E Perkins; Mariam AlHilli; Kristina A Butler; Sarah McKinstry; Stephanie Fink; Robert B Jenkins; Xiaonan Hou; Kimberly R Kalli; Karin M Goodman; Jann N Sarkaria; Beth Y Karlan; Amanika Kumar; Scott H Kaufmann; Lynn C Hartmann; Paul Haluska
Journal:  Clin Cancer Res       Date:  2014-01-07       Impact factor: 12.531

Review 2.  Patient-derived xenograft models in gynecologic malignancies.

Authors:  Clare L Scott; Helen J Mackay; Paul Haluska
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Authors:  Alessandra Decio; Marta Cesca; Francesca Bizzaro; Luca Porcu; Rossana Bettolini; Paolo Ubezio; Giulia Taraboletti; Dorina Belotti; Raffaella Giavazzi
Journal:  Clin Exp Metastasis       Date:  2015-07-17       Impact factor: 5.150

4.  A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.

Authors:  Hsin-Yao Tang; Lynn A Beer; Tony Chang-Wong; Rachel Hammond; Phyllis Gimotty; George Coukos; David W Speicher
Journal:  J Proteome Res       Date:  2011-11-18       Impact factor: 4.466

5.  Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer.

Authors:  Ning Zhang; Hua Zhu; Ye-Hao Dong; Lu Wang
Journal:  Oncol Lett       Date:  2019-07-02       Impact factor: 2.967

6.  The promise and challenge of ovarian cancer models.

Authors:  Noor Hasan; Anders W Ohman; Daniela M Dinulescu
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

7.  Establishment of an orthotopic transplantation tumor model of hepatocellular carcinoma in mice.

Authors:  Gui-Jun Zhao; Li-Xia Xu; Eagle S H Chu; Ning Zhang; Jia-Yun Shen; Alatangaole Damirin; Xiao-Xing Li
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

8.  In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

Authors:  M Apiranthitou-Drogari; C Paganin; S Bernasconi; G Losa; A Maneo; N Colombo; A Mantovani; P Allavena
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer.

Authors:  Francesca Ricci; Federica Guffanti; Roberta Affatato; Laura Brunelli; Pastorelli Roberta; Robert Fruscio; Patrizia Perego; Maria Rosa Bani; Giovanna Chiorino; Andrea Rinaldi; Francesco Bertoni; Maddalena Fratelli; Giovanna Damia
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.